Evaxion A/S

Evaxion is a pioneering TechBio company that uses its proprietary AI platform, AI-Immunology, to develop novel vaccines. This platform has been continuously developed and refined over the past 18 years and uses artificial intelligence to decode the human immune system. Evaxion has developed a pipeline of preclinical and clinical research and development programs, including therapeutic cancer vaccines (both personal and off-the-shelf) and prophylactic vaccines against bacterial and viral diseases with high unmet medical needs. The company plans to expand into autoimmune diseases. Evaxion's pipeline includes vaccines against pathogens for which no vaccines currently exist, such as *S. aureus*, Group A streptococcus, *N. gonorrhoeae*, and cytomegalovirus. The company aims to save and improve lives with AI-Immunology powered vaccines and creates value from both its AI-Immunology platform and its pipeline of vaccine candidates. The AI-Immunology platform can identify targets and suggest vaccine designs that conventional methods cannot. It is designed to be faster, cheaper, and more accurate, and can be scaled for application across more than 100 different diseases and used with various vaccine modalities. The platform improves through iterative learning loops, building on aggregated learnings and improvements. Its predictive power comes from its ability to process and interpret large amounts of complex biological data, transforming them into advanced algorithms to predict cellular interactions and identify targets for immune responses.